AI and Prescription Models: Promises and Realities

A Turning Point in Understanding Prescribers

For decades, knowledge of prescribing behavior relied on physician panels, aggregated sales data, and the experience of field teams. These sources remained valuable but partial: they described the past without genuinely anticipating the future. AI is changing that equation.

Prescription models — how a physician prescribes in a given indication, for which patient profiles, in what context — are becoming readable at an unprecedented level of granularity. Real-world reimbursement data, cross-referenced with external signals (publications, congresses, learned society guidelines), make it possible to build predictive models that identify practice shifts before they show up in sales figures.

What AI Models Enable in Practice

Dynamic prescriber segmentation. Clustering algorithms go well beyond the classic "high / medium / low prescriber" segmentation. It is now possible to distinguish the physician who prescribes rarely but in complex cases from the one who prescribes frequently as a first-line option — and to tailor medical engagement accordingly.

Detection of practice changes. When a prescriber significantly shifts their behavior, AI models detect this several weeks before it becomes visible in aggregated data. This enables medical teams to intervene at the right moment: understand, support, and respond to unexpressed questions.

Engagement plan optimization. By integrating behavioral data into MSL and medical delegate activity planning, teams can prioritize high-impact contacts and reduce low-value visits — a major concern in a context of shrinking access to prescribers.

The Limits That Cannot Be Ignored

These tools are only effective if the data feeding them is of high quality. Heterogeneous sources, missing data, or selection biases in the underlying panels produce models that confirm existing assumptions rather than challenge them.

Beyond data quality, regulatory compliance — GDPR, pharmaceutical promotion regulations — must be built in from the design phase, not bolted on at the end of the project. Legal and compliance teams must be involved from day one.

Our Take

AI applied to prescription models is not a revolution in the sense of replacing human expertise. It is an amplification: it allows medical teams to work from better information, ask better questions, and make better decisions. Organizations that integrate it methodically — starting from business needs, not from technology — gain a durable competitive advantage.